Patients with elevated Gal-3 concentrations presented a greater burden of comorbidities, with a higher prevalence of hypertension, diabetes, dyslipidemia, and parameters of greater clinical severity with higher concentrations of serum potassium and NT-proBNP. Here, LGALS3 is linked to metabolic syndrome.